Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Inclusion Criteria: * Participants with Asymptomatic Plasmodium falciparum Malaria with no Fever or other sign of Acute Uncomplicated Malaria and, with Microscopic confirmation using Giemsa-stained thick film, and a Parasitemia of \>= 40 to \<= 10,000 Asexual Parasites/Microliter (μL) of Blood. * Axillary Temperature \< 37.0 degree Celcius (ºC) or oral/Tympanic/rectal Temperature\< 37.5ºC; without history of fever during the previous 48 hours. * Have a body weight \>= 45 kilogram (kg) * Participants capable of giving Signed Informed consent which includes Compliance with the requirements and restriction listed in the Informed consent form * Other Protocol defined Inclusion Criteria could apply Exclusion Criteria: * Participants with any disease requiring Chronic Treatment * Participants with any Preplanned surgery during the study * Participants with any previous Treatment with pyronaridine as part of a combination therapy during the last 3 months * Participants with any adequate Hematological, Hepatic, and renal function as defined in the Protocol * Other protocol defined Exclusion Criteria could apply